With regard to the use and cost paid by the government for prescribed medical marijuana and prescribed pharmaceuticals used by members of the Canadian Armed Forces and veterans of the Canadian Armed Forces, and administered by Veterans Affairs Canada: (a) what was the total amount paid annually, broken down by year from 2015 up to the current year, 2019, for (i) medical marijuana, (ii) Diazepam, (iii) Clonazepam, (iv) Trazodone, (v) Zopièlone, (vi) Wellbutrin, (vii) Effexor, (viii) Celexa, (ix) Seroquel, (x) Ambien, (xi) Remeron, (xii) Nabilone, (xiii) Valium, (xiv) Prazosin, (xv) Oxycodone, (xvi) Demerol, (xvii) Dilaudid, (xviii) Fentanyl, (xix) Mirtazapine, (xx) Gabapentin, (xxi) Baclofen, (xxii) Propranolol, (xxiii) Targin, (xxiv) Pantoprazole, (xxv) Nortriptyline, (xxvi) Ketoconazole, (xxvii) prescribed pharmaceuticals, including opioids and other pain relief medications; and (b) what evidence, reports, scientific studies or otherwise have been used as a reference or a basis for the use, prescription or non-use or non-prescription of the pharmaceuticals or medical marijuana?
In the House of Commons on April 9th, 2019. See this statement in context.